Nevertheless, baseline differences in the top 45 differential splicing events in glioblastoma can form a splicing signature that seems to differentiate between good and poor responders to PRMT5 inhibition better than mutational status [137]. This evidence concerns the gene PRMT5 and glioblastoma.